|
IT951631B
(it)
|
1971-03-18 |
1973-07-10 |
Richardson Merrell Spa |
Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi
|
|
GB8604528D0
(en)
|
1986-02-24 |
1986-04-03 |
Ici Plc |
Therapeutic agents
|
|
US6881548B2
(en)
|
1997-05-23 |
2005-04-19 |
A&G Pharmaceutical, Inc. |
Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
|
|
US6638727B1
(en)
|
1999-01-26 |
2003-10-28 |
Cytyc Health Corporation |
Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
|
|
US6398765B1
(en)
|
1999-03-01 |
2002-06-04 |
Pro Duct Health, Inc. |
Apparatus, methods and kits for simultaneous delivery of a substance to multiple breast milk ducts
|
|
US6245352B1
(en)
|
1999-04-27 |
2001-06-12 |
Eli Lilly And Company |
Pharmaceutical formulation
|
|
WO2001001962A1
(en)
|
1999-07-05 |
2001-01-11 |
Idea Ag. |
A method for the improvement of transport across adaptable semi-permeable barriers
|
|
GB0000313D0
(en)
|
2000-01-10 |
2000-03-01 |
Astrazeneca Uk Ltd |
Formulation
|
|
GB0008172D0
(en)
|
2000-04-05 |
2000-05-24 |
Astrazeneca Ab |
Therapy
|
|
WO2003039530A1
(en)
|
2001-11-07 |
2003-05-15 |
Synthon B.V. |
Tamsulosin tablets
|
|
EP1572178B1
(en)
|
2002-12-18 |
2006-05-03 |
Laboratoires Besins International |
Treatment of mastalgia with 4-hydroxy tamoxifen
|
|
EP2050443B1
(en)
|
2002-12-18 |
2017-05-24 |
Besins Healthcare Luxembourg SARL |
Reduction of breast density with 4-hydroxy tamoxifen
|
|
CA2519980C
(en)
|
2003-04-01 |
2012-04-10 |
Laboratoires Besins International |
Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
|
|
NZ544851A
(en)
|
2003-06-23 |
2008-03-28 |
Macrochem Corp |
A vanishing cream base composition suitable for topical administration of an active agent to an animal or plant
|
|
US7531578B2
(en)
|
2003-09-18 |
2009-05-12 |
City Of Hope |
Compounds and methods for treating breast cancer and other diseases
|
|
US7968532B2
(en)
|
2003-12-15 |
2011-06-28 |
Besins Healthcare Luxembourg |
Treatment of gynecomastia with 4-hydroxy tamoxifen
|
|
ATE548375T1
(de)
|
2004-01-16 |
2012-03-15 |
Cedarburg Pharmaceuticals Inc |
Exemestan und zwischenprodukte davon und verfahren zu dessen herstellung
|
|
US8436029B2
(en)
|
2004-03-19 |
2013-05-07 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical forms, and methods of making and using the same
|
|
US7507769B2
(en)
|
2004-03-22 |
2009-03-24 |
Laboratoires Besins International |
Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
|
|
CA2603857A1
(en)
|
2005-03-31 |
2006-11-16 |
Mytogen, Inc. |
Treatment for heart disease
|
|
US20060280795A1
(en)
*
|
2005-06-08 |
2006-12-14 |
Dexcel Pharma Technologies, Ltd. |
Specific time-delayed burst profile delivery system
|
|
KR100917698B1
(ko)
|
2005-07-06 |
2009-09-21 |
시코르, 인크. |
레트로졸의 제조를 위한 개선된 방법
|
|
CA2617934A1
(en)
|
2005-08-05 |
2007-02-15 |
Nuvo Research Inc. |
Transdermal drug delivery formulation
|
|
US8034824B2
(en)
|
2005-10-12 |
2011-10-11 |
Kowa Co., Ltd. |
Iontophoretic preparation for treatment of breast cancer and/or mastitis
|
|
WO2007067773A2
(en)
|
2005-12-09 |
2007-06-14 |
Mayo Foundation For Medical Education And Research |
Assessing outcomes for breast cancer patients by determining cyp2d6 genotype
|
|
ES2540561T3
(es)
|
2005-12-20 |
2015-07-10 |
Incyte Corporation |
N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
|
|
US9308181B2
(en)
|
2006-03-06 |
2016-04-12 |
Nuvo Research Inc. |
Topical formulations, systems and methods
|
|
US8058302B2
(en)
|
2006-06-05 |
2011-11-15 |
Cadila Healthcare Limited |
Process for preparing pure anastrozole
|
|
US20100098735A1
(en)
|
2006-10-05 |
2010-04-22 |
Rajesh Jain |
Injectable depot compositions and its process of preparation
|
|
PT2101731T
(pt)
|
2006-11-21 |
2018-04-18 |
Jina Pharmaceuticals Inc |
Endoxifeno para utilização no tratamento de cancro
|
|
US20090291134A1
(en)
|
2006-11-21 |
2009-11-26 |
Jina Pharmaceuticals, Inc. |
Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
|
|
US20120164075A1
(en)
*
|
2006-11-21 |
2012-06-28 |
Jina Pharmaceuticals, Inc. |
Endoxifen methods and compositions in the treatment of mammalian diseases
|
|
WO2008066783A2
(en)
*
|
2006-11-27 |
2008-06-05 |
Ariad Pharmaceuticals, Inc. |
Therapeutic materials and methods
|
|
WO2008067991A2
(en)
|
2006-12-08 |
2008-06-12 |
Antares Pharma Ipl Ag |
Skin-friendly drug complexes for transdermal administration
|
|
WO2008113177A1
(en)
|
2007-03-20 |
2008-09-25 |
Centre De Recherche Sur Les Biotechnologies Marines |
Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
|
|
US8454945B2
(en)
|
2007-03-22 |
2013-06-04 |
Berg Pharma Llc |
Topical formulations having enhanced bioavailability
|
|
US20090068190A1
(en)
|
2007-08-29 |
2009-03-12 |
Drugtech Corporation |
Anti-proliferative combinations
|
|
AR068409A1
(es)
|
2007-09-14 |
2009-11-18 |
Drugtech Corp |
Composiciones farmaceuticas, transdermicas sin alcohol
|
|
EP2212301B1
(en)
|
2007-11-28 |
2012-02-29 |
Fresenius Kabi Oncology Limited |
An improved process for preparation of letrozole and its intermediates
|
|
WO2009120999A2
(en)
|
2008-03-28 |
2009-10-01 |
Olema Pharmaceuticals, Inc. |
Use of an endoxifen prodrug for treatment of breast cancer
|
|
WO2009129352A2
(en)
|
2008-04-15 |
2009-10-22 |
Windy Hill Medical |
Device and method for accessing and treating ducts of mammary glands
|
|
US8063249B1
(en)
|
2008-04-25 |
2011-11-22 |
Olema Pharmaceuticals, Inc. |
Substituted triphenyl butenes
|
|
CA3012229C
(en)
|
2008-07-08 |
2020-11-10 |
Incyte Holdings Corporation |
1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
|
|
WO2010009335A1
(en)
|
2008-07-17 |
2010-01-21 |
Micell Technologies, Inc. |
Drug delivery medical device
|
|
WO2010043404A1
(en)
|
2008-10-15 |
2010-04-22 |
Synthon B.V. |
Processes and intermediates for the production of fulvestrant
|
|
US20100098659A1
(en)
|
2008-10-22 |
2010-04-22 |
Revalesio Corporation |
Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
|
|
ES2624557T3
(es)
|
2008-12-11 |
2017-07-14 |
Besins Healthcare Luxembourg Sarl |
Composiciones farmacéuticas transdérmicas que comprenden un SERM
|
|
CN101891635B
(zh)
|
2009-05-21 |
2014-06-04 |
扬子江药业集团有限公司 |
枸橼酸他莫昔芬的晶型及晶型a的制备方法
|
|
US9132084B2
(en)
|
2009-05-27 |
2015-09-15 |
Neothetics, Inc. |
Methods for administration and formulations for the treatment of regional adipose tissue
|
|
US20100317635A1
(en)
|
2009-06-16 |
2010-12-16 |
Endorecherche, Inc. |
Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
|
|
CN102470105B
(zh)
|
2009-07-14 |
2015-07-29 |
波利皮得有限公司 |
持续释放药物载体组合物
|
|
WO2011031561A2
(en)
|
2009-08-27 |
2011-03-17 |
Ensisheim Partners Llc |
Nucleic acid molecules and uses thereof
|
|
US8637569B2
(en)
|
2009-10-22 |
2014-01-28 |
Api Genesis, Llc |
Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
|
|
WO2011072244A1
(en)
|
2009-12-10 |
2011-06-16 |
Mount Sinai School Of Medicine Of New York University |
Method of treatment of breast cancer with tamoxifen
|
|
EP2425833A1
(de)
|
2010-09-03 |
2012-03-07 |
Fresenius Kabi Deutschland GmbH |
Die intravenöse Applikation von Fischöl/DHA +EPA vor bzw. mit Beginn der Chemotherapie
|
|
KR101308258B1
(ko)
|
2010-10-15 |
2013-09-13 |
씨제이제일제당 (주) |
엔독시펜의 신규한 제조 방법
|
|
EP2468264A1
(en)
|
2010-12-27 |
2012-06-27 |
Laboratorios Liconsa, S.A. |
Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
|
|
US9200045B2
(en)
|
2011-03-11 |
2015-12-01 |
President And Fellows Of Harvard College |
Small molecule-dependent inteins and uses thereof
|
|
EP2508174A1
(en)
*
|
2011-04-06 |
2012-10-10 |
Ljiljana Sovic Brkicic |
Pharmaceutical composition
|
|
WO2012162492A1
(en)
*
|
2011-05-24 |
2012-11-29 |
Teva Pharmaceutical Industries Ltd. |
Compressed core comprising organic acids for a pharmaceutical composition
|
|
WO2013033430A1
(en)
|
2011-09-02 |
2013-03-07 |
Wake Forest School Of Medicine |
Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
|
|
FR2980972B1
(fr)
|
2011-10-05 |
2014-02-28 |
Commissariat Energie Atomique |
Formulations pour le diagnostic et le traitement de cancers hormonodependants et de cancers des organes de synthese d'hormones steroidiennes.
|
|
WO2013134230A1
(en)
|
2012-03-05 |
2013-09-12 |
Xavier University |
Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer
|
|
US9220680B2
(en)
|
2012-07-13 |
2015-12-29 |
South Dakota State University |
Compositions and methods for localized drug delivery through mammary papillae
|
|
US20150321983A1
(en)
|
2012-10-19 |
2015-11-12 |
Fermion Oy |
A process for the preparation of ospemifene
|
|
EP2922847A1
(en)
|
2012-11-20 |
2015-09-30 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
|
|
IL298125A
(en)
|
2013-02-26 |
2023-01-01 |
Memorial Sloan Kettering Cancer Center |
Preparations and methods for immunotherapy
|
|
WO2014141292A2
(en)
|
2013-03-04 |
2014-09-18 |
Intas Pharmaceuticals Limited |
Endoxifen citrate polymorph and process for preparing the same
|
|
CN105492011A
(zh)
|
2013-04-08 |
2016-04-13 |
丹尼斯·M·布朗 |
不理想给药化学化合物的治疗增效
|
|
TW201536278A
(zh)
|
2013-05-31 |
2015-10-01 |
Del Mar Pharmaceuticals |
雙脫水半乳糖醇及其類似物與衍生物用於治療復發性惡性神經膠瘤或進行性繼發腦瘤之用途
|
|
EP3057985A4
(en)
|
2013-10-18 |
2017-05-31 |
The Regents Of The University Of Michigan |
Systems and methods for determining a treatment course of action
|
|
HUP1300646A2
(en)
|
2013-11-12 |
2015-05-28 |
Druggability Technologies Ip Holdco Jersey Ltd |
Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
|
|
EP3092027A4
(en)
|
2014-01-10 |
2017-09-06 |
Atossa Genetics Inc. |
Transpapillary methods and compositions for diagnosing and treating breast conditions
|
|
US9744177B2
(en)
|
2014-03-10 |
2017-08-29 |
Endorecherche, Inc. |
Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
|
|
CA2942301A1
(en)
|
2014-03-11 |
2015-09-17 |
Repros Therapeutics Inc. |
Clomiphene synthesis using a single solvent
|
|
EP3152579A4
(en)
|
2014-06-04 |
2018-01-17 |
Atossa Genetics Inc. |
Molecular mammography
|
|
CN104230723B
(zh)
|
2014-08-21 |
2016-08-24 |
凯莱英医药集团（天津）股份有限公司 |
托瑞米芬的合成方法
|
|
EP3283061A4
(en)
|
2015-04-14 |
2019-04-17 |
Atossa Genetics Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF BREAST DISEASES AND ORGANISM-RELATED ILLNESSES
|
|
WO2016187122A1
(en)
|
2015-05-15 |
2016-11-24 |
University Of Iowa Research Foundation |
Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy
|
|
CA2992282A1
(en)
|
2015-07-14 |
2017-01-19 |
Atossa Genetics Inc. |
Transpapillary methods and compositions for treating breast disorders
|
|
ES2883172T3
(es)
|
2015-10-22 |
2021-12-07 |
Us Health |
Proceso para preparar (Z)-endoxifeno de alta pureza
|
|
DE102015222031A1
(de)
|
2015-11-10 |
2017-05-11 |
Robert Bosch Gesellschaft Für Medizinische Forschung Mbh |
Synthese von (Z)-Endoxifenhydrochlorid
|
|
US20170304232A1
(en)
|
2016-04-20 |
2017-10-26 |
Northwestern University |
Endoxifen For Local Transdermal Therapy To The Breast
|
|
CN111212635A
(zh)
|
2017-09-11 |
2020-05-29 |
阿托莎医疗公司 |
局部用组合物
|
|
TW201919594A
(zh)
|
2017-09-11 |
2019-06-01 |
美商艾陶莎基因有限公司 |
局部用組合物及治療方法
|
|
EP3681491A4
(en)
*
|
2017-09-11 |
2021-06-30 |
Atossa Therapeutics, Inc. |
PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES
|
|
WO2021003433A1
(en)
*
|
2019-07-03 |
2021-01-07 |
Atossa Therapeutics, Inc. |
Sustained release compositions of endoxifen
|